Engineered immune cells take on deadly brain tumors
NCT ID NCT02208362
First seen Nov 01, 2025 · Last updated May 03, 2026 · Updated 28 times
Summary
This early-phase study tests a new immunotherapy for people with malignant glioma that has returned or not responded to standard treatment. Researchers take a patient's own T-cells (a type of immune cell), add a gene that helps them recognize and attack glioma cells, and infuse them back into the patient. The main goals are to find the safest dose and understand side effects, with 65 participants enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
Conditions
Explore the condition pages connected to this study.